• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services


  • Print
  • Share
  • E-mail

Valganciclovir (marketed as Valcyte) Information

Valcyte (valganciclovir) is indicated for:

Adult Patients

  • Treatment of Cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS).
  • Prevention of CMV disease in kidney, heart, or kidney-pancreas transplant patients at high risk.

Pediatric Patients

  • Prevention of CMV disease in kidney or heart transplant patients at high risk.

To report any serious adverse events associated with the use of this drug, please contact the FDA MedWatch program using the contact information at the bottom of this page.


Contact FDA

1-800-FDA-0178 Fax
Report a Serious Problem

MedWatch Online

Regular Mail: Use postage-paid FDA Form 3500

Mail to: MedWatch 5600 Fishers Lane

Rockville, MD 20857